Table 2.
Clinical, laboratory, and ART information of HIV infected children receiving ART in Amhara Region Referral Hospitals from January 1, 2012 to February 28, 2017
| Variables | Frequency (N) | Percentage (%) |
|---|---|---|
| OI at baseline | ||
| Yes | 242 | 45.0 |
| No | 296 | 55.0 |
| Functional status (age ≥ 5 years) (N = 347) | ||
| Working | 195 | 56.2 |
| Ambulatory | 144 | 41.5 |
| Bedridden | 8 | 2.3 |
| Developmental history (age < 5 years) (N = 191) | ||
| Appropriate | 143 | 74.9 |
| Delayed | 40 | 20.9 |
| Regressive | 8 | 4.2 |
| WHO clinical staging | ||
| Stage I and II | 310 | 57.6 |
| Stage III and IV | 228 | 42.4 |
| Past TB test before ART | ||
| Not determined | 430 | 80.0 |
| Negative | 53 | 9.9 |
| Positive | 55 | 10.1 |
| Past TB treatment | ||
| No treatment | 483 | 89.8 |
| 2SRHZ/4RH | 38 | 7.1 |
| 2HRZES/4HRE | 4 | 0.8 |
| HRZE/4RH | 13 | 2.4 |
| CD4 count or percent | ||
| Severe immunodeficiency | 374 | 69.5 |
| Mild immunodeficiency | 164 | 30.5 |
| Hemoglobin level | ||
| Anemic(< 10 g/dl) | 66 | 12.3 |
| Non-anemic (≥10 g/dl) | 472 | 87.7 |
| ART eligibility criteria | ||
| Immunologic/ CD4 | 134 | 24.9 |
| WHO clinical stage | 67 | 12.5 |
| Both clinical and immunologic | 216 | 40.2 |
| Test and treat approach | 121 | 22.5 |
| Cotrimoxazole preventive therapy | ||
| Yes | 340 | 63.2 |
| No | 198 | 36.8 |
| ART adherence in the 1st 3 months | ||
| Good /fair | 495 | 92.2 |
| Poor | 42 | 7.8 |
| Underweight (baseline) | ||
| Normal | 317 | 58.9 |
| Moderate (WAZ < - 2) | 128 | 23.8 |
| Severe (WAZ < −3) | 93 | 17.3 |
| Stunting (baseline) | ||
| Normal | 336 | 62.5 |
| Moderate (HAZ < −2) | 80 | 14.9 |
| Severe (HAZ < −3) | 122 | 22.7 |
| Wasting (baseline) | ||
| Normal | 365 | 67.8 |
| Moderate (WHZ or BAZ < −2) | 83 | 15.4 |
| Severe (WHZ or BAZ < − 3) | 90 | 16.7 |